Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminogen Activator Using a Decapeptide Antagonist. Evidence for a Composite Ligand-Binding Site and a Short Interdomain Separation
- 25 February 1998
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (11) , 3612-3622
- https://doi.org/10.1021/bi972787k
Abstract
Binding of urokinase-type plasminogen activator (uPA) to its cellular receptor (uPAR) renders the cell surface a favored site for plasminogen activation. Recently, a 15-mer peptide antagonist of the uPA-uPAR interaction, with an IC50 value of 10 nM, was identified using phage display technology [Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) Proc. Natl. Acad. Sci. 91, 7129-7133]. In the present study, the molecular aspects of the interaction between this peptide and uPAR have been investigated. We have characterized the real-time receptor binding kinetics for the antagonist using surface plasmon resonance and identified critical residues by alanine replacements. The minimal peptide antagonist thus derived (SLNFSQYLWS) was rendered photoactivatable by replacing residues important for uPAR binding with photochemically active derivatives of phenylalanine containing either (trifluoromethyl)diazirine or benzophenone. These peptides incorporated covalently into purified soluble uPAR upon photoactivation, and this was inhibited by preincubation with receptor binding derivatives of uPA. The intact three-domain structure of uPAR was essential for efficient photoaffinity labeling. Proteolytic domain mapping using chymotrypsin revealed a specific labeling of both uPAR domain I and domains II + III dependent on the position of the photoprobe in the antagonist. On the basis of these studies, we propose the existence of a composite ligand binding site in uPAR combined of residues located in distinct structural domains. According to this model, a close spatial proximity between uPAR domain I and either domains II or III in intact uPAR is required for the assembly of this composite binding site. Since the receptor binding properties of the peptide antagonist closely mimic those of uPA itself, these two ligands presumably share coincident binding site in uPAR.Keywords
This publication has 19 references indexed in Scilit:
- 175 Different mechanisms are involved in the antibody mediated inhibition of the interaction between the urokinase-type plasminogen activator and its receptorFibrinolysis and Proteolysis, 1997
- Domain Interplay in the Urokinase ReceptorJournal of Biological Chemistry, 1996
- Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxinsFEBS Letters, 1994
- Design, synthesis, and properties of a photoactivatable membrane-spanning phospholipidic probeJournal of the American Chemical Society, 1993
- A soluble form of the glycolipid‐anchored receptor for urokinase‐type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuriaEuropean Journal of Biochemistry, 1992
- Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical systemJournal of Immunological Methods, 1991
- Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptorFEBS Letters, 1991
- In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.The Journal of cell biology, 1988
- A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.The Journal of cell biology, 1985
- 4'-(1-Azi-2,2,2-trifluoroethyl)phenylalanine, a photolabile carbene-generating analog of phenylalanineJournal of the American Chemical Society, 1984